Dulaglutide 3mg/0.5ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Dulaglutide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Dulaglutide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Dulaglutide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Dulaglutide on the MHRA register
Trulicity 3mg/0.5ml solution for injection pre-filled pens
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
160 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Type 2 diabetes in adults: management (NG28)
Tirzepatide for treating type 2 diabetes (TA924)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 19 · Randomised trials: 28 · 2014–2026
Showing the 50 most relevant studies, sorted by most relevant.
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet, 2019
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet, 2019
- Albuminuria
- Creatinine
- Diabetes Mellitus, Type 2
Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay, et al.
The Lancet Diabetes & Endocrinology, 2018
- Semaglutide
- Blood Glucose
- Body Weight
Katherine R Tuttle, Mark Lakshmanan, Brian Rayner, et al.
The Lancet Diabetes & Endocrinology, 2018
- Insulin Glargine
- Blood Glucose
- Diabetes Mellitus, Type 2
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, et al.
Diabetologia, 2020
- Liraglutide
- Alanine Transaminase
- Aspartate Aminotransferases
Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, et al.
The Lancet Diabetes & Endocrinology, 2020
- Semaglutide
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, et al.
The Lancet Diabetes & Endocrinology, 2022
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptide-1 Receptor
- Tirzepatide
Bernhard Ludvik, Juan P. Frías, Francisco J. Tinahones, et al.
The Lancet Diabetes & Endocrinology, 2018
- Sodium-Glucose Transporter 2 Inhibitors
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
Juan P. Frías, Enzo Bonora, Luis Nevárez Ruiz, et al.
Diabetes Care, 2021
- Diabetes Mellitus, Type 2
- Metformin
- Glucagon-Like Peptides
Kathleen Dungan, Santiago Tofé Povedano, Thomas Först, et al.
The Lancet, 2014
- Liraglutide
- Analysis of Variance
- Blood Glucose
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3.75 days
Mechanism
Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increas…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
24-48 hours
[L34670]
In a pharmacokinetic study of 20 healthy adults, Cmax occurred within 24-48 hours after dosing.
[A234419]
…
Half-life
3.75 days
Protein binding
[L30380][L34670]
Volume of distribution
3.09 L
[L30380]
…
Metabolism
[L30380]
Elimination
[L30380]
Clearance
0.142 L/h
[L30380]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L30380]
It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
[L30380]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 976 interactions
[L34685]
Cases of overdose with dulaglutide have resulted in gastrointestinal disturbance. Appropriate supportive treatment is recommended to manage signs and symptoms.
[L34670]
Additionally, hypoglycemia has been observed after an overdose with dulaglutide; frequent plasma glucose monitoring should be performed.
[L30380]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L34670]
In a pharmacokinetic study of 20 healthy adults, Cmax occurred within 24-48 hours after dosing.
[A234419]
The average absolute bioavailability of dulaglutide after subcutaneous injections of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively.
[L30380]
[A234419]
Prescribing information indicates a half-life of approximately 5 days.
[L30380]
[L30380][L34670]
[L30380]
[L30380]
[L30380]
[L30380]
Proteins and enzymes this drug interacts with in the body
PMID:19861722 PMID:26308095 PMID:27196125 PMID:28514449 PMID:7517895 PMID:8216285 PMID:8405712
Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels .
PMID:19861722 PMID:26308095 PMID:27196125 PMID:28514449 PMID:7517895 PMID:8216285 PMID:8405712
Plays a role in regulating insulin secretion in response to GLP-1 (By similarity)
ATC A10BJ05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Dulaglutide
Additional database identifiers
Drugs Product Database (DPD)
22660
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4324
GenAtlas
GLP1R
GeneCards
GLP1R
GenBank Gene Database
U01104
GenBank Protein Database
405082
Guide to Pharmacology
249
UniProt Accession
GLP1R_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72